Analysis
Attovia Therapeutics priced its initial public offering at $17.00 per share, selling 17 million shares for $289 million in gross proceeds and listing on Nasdaq under ATTO, according to IPOScoop's 2026 pricing table. The pricing followed an S-1/A amendment filed with the SEC on August 4.
It is the only operating company to price in the first week of August. The other listings that came to market on August 4 and 5 -- TCGX Acquisition, ARC Group Securities Acquisition I and BOA Acquisition Corp. II -- were blank-check vehicles at the standard $10 unit price. That mix is the honest picture of the current window: biotech and SPACs, not technology.
“The other listings that came to market on August 4 and 5 -- TCGX Acquisition, ARC Group Securities Acquisition I and BOA Acquisition Corp.”
For scale, Apnimed priced at $16 on July 31 and returned 56% on its first day, which is the kind of print that pulls the next cohort of biotech issuers off the sidelines. Attovia's raise is roughly double Apnimed's and lands in a tape where the S&P 500 and Dow both set records this week -- about as favorable a backdrop as a clinical-stage issuer gets.
The larger context is that 2026 has produced 217 US IPOs so far, about 6.9% more than the same point in 2025, and Goldman Sachs projected US IPO proceeds could reach a record $160 billion this year if the marquee names come. SpaceX listed in June. OpenAI and Anthropic have both filed confidentially. Attovia is not that story -- it is the ordinary mid-cap biotech flow that keeps the calendar alive between the headline deals.
What to watch: the first-day and first-week trading, and whether the remaining biotech S-1/A amendments on file -- Latigo Biotherapeutics amended on August 3 -- follow Attovia to pricing in the next two weeks. A clean debut here reopens the biotech window for September; a broken one closes it.
